leadf
logo-loader
viewTiziana Life Sciences PLC

Tiziana Life Sciences is pioneering a novel approach to COVID-19 treatment, says analyst

“To date, trials of anti-IL6R mAbs have as far as we know focused largely on intravenous (IV) or subcutaneous route of administration."

Tiziana Life Sciences PLC -

Tiziana Life Sciences PLC (LON:TILS NASDAQ:TLSA) is driving forwards at speed with the clinical development plan for its fully-human mAb TZLS-501 COVID-19 treatment, according to Emma Uiker at Proactive Research.

With GMP-grade manufacturing already underway via boutique CRO, STC Biologics, Tiziana has appointed three other CROs to develop and test the handheld nebuliser, to conduct an inhalation safety toxicity study in monkeys, and to initiate a human clinical trial in COVID-19 patients.

Tiziana has also taken an innovative approach to leverage the potential of TZLS-501 to treat COVID-19, to investigate its promise of helping alleviate life-threatening lung inflammation, says Uiker.

“To our knowledge TILS is a pioneer in developing anti-IL6R mAbs for administration via a nebuliser or inhaler direct to the lungs and recently filed a patent on the approach in order to target the main site of inflammation directly.

“To date, trials of anti-IL6R mAbs have as far as we know focused largely on intravenous (IV) or subcutaneous route of administration.

“The inhaler approach can enable patients to be treated quickly and easily, including potentially outside the hospital setting.”

To read the full note, click here

Quick facts: Tiziana Life Sciences PLC

Price: 142 GBX

AIM:TILS
Market: AIM
Market Cap: £271.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

5 days, 10 hours ago

2 min read